We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
Read MoreHide Full Article
Vanda Pharmaceuticals Inc. (VNDA - Free Report) generates revenues from the sale of its three commercial products, Fanapt, Hetlioz and Ponvory.
Fanapt is approved in the United States for two indications, schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. Hetlioz is approved to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome.
Ponvory is an oral treatment approved to treat relapsing forms of multiple sclerosis. VNDA acquired the United States and Canada rights to Ponvory from Actelion Pharmaceuticals Limited, a subsidiary of Johnson & Johnson (JNJ - Free Report) , in December 2023.
JNJ gained approval for Ponvory as an oral treatment for adults with relapsing forms of multiple sclerosis in 2021.
VNDA Stock's Price Performance
In the past year, shares of Vanda have gained 13.9% against the industry’s decline of 16%.
Image Source: Zacks Investment Research
Beside the three marketed products, Vanda has a promising pipeline targeting various indications in neuroscience, immunology and oncology.
Management plans to submit regulatory filings with the FDA for two pipeline candidates, tradipitant (for preventing vomiting induced by motion sickness) and milsaperidone (for schizophrenia and acute bipolar I disorder indications) shortly.
Successful development and potential approval of these candidates should help VNDA diversify its commercial portfolio and drive long-term growth.
Last month, the FDA granted an Orphan Drug designation to another pipeline candidate, VGT-1849A for treating polycythemia vera (PV), a rare hematologic malignancy.
VNDA is developing VGT-1849A, a novel antisense oligonucleotide (ASO)-based JAK2 inhibitor for treating PV and other JAK2-driven hematologic malignancies.
In the past 60 days, estimates for Vanda’s 2025 loss per share have narrowed from 53 cents to 35 cents.
With a sound cash position and some clinical milestones expected later this year, investor focus remains on the VNDA stock.
Other Stocks to Consider
Some other top-ranked stocks from the biotech sector are Puma Biotechnology, Inc. (PBYI - Free Report) and Castle Biosciences, Inc. (CSTL - Free Report) , each sporting a Zacks Rank #1 at present.
In the past 60 days, estimates for Puma Biotechnology’s 2025 earnings per share have increased from 42 cents to 54 cents. In the past year, shares of PBYI have declined 38.8%.
PBYI’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.78%.
In the past 60 days, Castle Biosciences’ loss per share estimates for 2025 have narrowed from $1.88 to $1.84. In the past year, shares of CSTL have surged 30.9%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
Vanda Pharmaceuticals Inc. (VNDA - Free Report) generates revenues from the sale of its three commercial products, Fanapt, Hetlioz and Ponvory.
Fanapt is approved in the United States for two indications, schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. Hetlioz is approved to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome.
Ponvory is an oral treatment approved to treat relapsing forms of multiple sclerosis. VNDA acquired the United States and Canada rights to Ponvory from Actelion Pharmaceuticals Limited, a subsidiary of Johnson & Johnson (JNJ - Free Report) , in December 2023.
JNJ gained approval for Ponvory as an oral treatment for adults with relapsing forms of multiple sclerosis in 2021.
VNDA Stock's Price Performance
In the past year, shares of Vanda have gained 13.9% against the industry’s decline of 16%.
Image Source: Zacks Investment Research
Beside the three marketed products, Vanda has a promising pipeline targeting various indications in neuroscience, immunology and oncology.
Management plans to submit regulatory filings with the FDA for two pipeline candidates, tradipitant (for preventing vomiting induced by motion sickness) and milsaperidone (for schizophrenia and acute bipolar I disorder indications) shortly.
Successful development and potential approval of these candidates should help VNDA diversify its commercial portfolio and drive long-term growth.
Last month, the FDA granted an Orphan Drug designation to another pipeline candidate, VGT-1849A for treating polycythemia vera (PV), a rare hematologic malignancy.
VNDA is developing VGT-1849A, a novel antisense oligonucleotide (ASO)-based JAK2 inhibitor for treating PV and other JAK2-driven hematologic malignancies.
VNDA's Zacks Rank & Rising Estimates
Vanda currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Vanda’s 2025 loss per share have narrowed from 53 cents to 35 cents.
With a sound cash position and some clinical milestones expected later this year, investor focus remains on the VNDA stock.
Other Stocks to Consider
Some other top-ranked stocks from the biotech sector are Puma Biotechnology, Inc. (PBYI - Free Report) and Castle Biosciences, Inc. (CSTL - Free Report) , each sporting a Zacks Rank #1 at present.
In the past 60 days, estimates for Puma Biotechnology’s 2025 earnings per share have increased from 42 cents to 54 cents. In the past year, shares of PBYI have declined 38.8%.
PBYI’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.78%.
In the past 60 days, Castle Biosciences’ loss per share estimates for 2025 have narrowed from $1.88 to $1.84. In the past year, shares of CSTL have surged 30.9%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.